Nearly 8% of the human population carries an inactivating point mutation in the gene that encodes the cardioprotective enzyme aldehyde dehydrogenase 2 (ALDH2). This genetic polymorphism (ALDH2*2) is linked to more severe outcomes from ischemic heart damage and an increased risk of coronary artery disease (CAD), but the underlying molecular bases are unknown. We investigated the ALDH2*2 mechanisms in a human model system of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) generated from individuals carrying the most common heterozygous form of the ALDH2*2 genotype. We showed that the ALDH2*2 mutation gave rise to elevated amounts of reactive oxygen species and toxic aldehydes, thereby inducing cell cycle arrest and activation of apoptotic signaling pathways, especially during ischemic injury. We established that ALDH2 controls cell survival decisions by modulating oxidative stress levels and that this regulatory circuitry was dysfunctional in the loss-offunction ALDH2*2 genotype, causing up-regulation of apoptosis in cardiomyocytes after ischemic insult. These results reveal a new function for the metabolic enzyme ALDH2 in modulation of cell survival decisions. Insight into the molecular mechanisms that mediate ALDH2*2-related increased ischemic damage is important for the development of specific diagnostic methods and improved risk management of CAD and may lead to patient-specific cardiac therapies.
INTRODUCTION
Heart failure is a leading cause of death worldwide, with coronary artery disease (CAD) and stroke together killing more than 10 million people annually. The single-nucleotide polymorphism that generates a Glu-toLys change at position 487 (E487K) of the cardioprotective enzyme aldehyde dehydrogenase 2 (ALDH2*2) (1, 2) has been linked to both an increased risk of CAD and more severe outcomes (3-6), a higher incidence of hypertension and cancer, and an increase in complications from type 2 diabetes (7-9). The ALDH2*2 genotype is present in~8% of the human population, predominantly in people of East Asian heritage.
CAD causes cardiomyocytes to experience ischemic challenge that results in altered metabolism and elevated oxidative stress. During myocardial infarction (MI), reactive oxygen species (ROS) cause oxidative damage, including lipid peroxidation and enhanced production of toxic aldehydes such as 4-hydroxynonenal (4HNE) (2, (10) (11) (12) . Furthermore, dysregulation of ROS-mediated signaling events during ischemia and reperfusion is known to trigger apoptosis and necrosis in heart tissue (13) . Mitochondrial ALDH2 fulfills a critical role in metabolic health as a detoxifying enzyme of reactive aldehydes that are generated by ROS, such as 4HNE (2, 12, 14) , and as a beneficial factor in acetaldehydeassociated and aging-induced cardiovascular complications (15) (16) (17) (18) . Moreover, bioactivation of the vasodilator nitroglycerin is catalyzed by ALDH2 and is impaired in carriers of the ALDH2*2 polymorphism (19) (20) (21) . Oxidative stress and nitroglycerin tolerance are caused by inactivation of cardioprotective ALDH2, which is associated with cardiac dysfunction and increased infarct size after MI (19, 22, 23) . Specific activation of mitochondrial ALDH2 has been shown to overcome ischemic heart damage (2, 19, (23) (24) (25) .
In heterozygous carriers of the dominant-negative ALDH2*2 genotype, the enzymatic activity of ALDH2 is reduced to less than 40% of wild type (26) , thereby rendering ALDH2*2 carriers more susceptible to oxidative damage. In addition, previous studies have shown that toxic aldehydes such as 4HNE rapidly inactivate ALDH2 (2) . 4HNE also acts as a signaling molecule that modulates transcriptional regulation (27) , causing cell cycle arrest and activation of proapoptotic pathways, as well as inflammatory pain (27) (28) (29) (30) .
The mechanism by which the nonbenign ALDH2*2 genotype (7, 9, 31) causes more severe outcomes from ischemic heart damage has not been studied in human cardiomyocytes at the cellular level. Here, we hypothesize that increased levels of ROS and 4HNE in ALDH2*2 cells not only affect the metabolic balance (11, 16, 32) but also cause dysregula
RESULTS
Correlation of ALDH2*2 polymorphism with elevated 4HNE and ROS To characterize the phenotype of the ALDH2*2 mutation, we recruited a cohort of 10 age-and sex-matched East Asian individuals who carried either the common heterozygous mutation ALDH2*2/1 or the ALDH2 wild-type gene (Fig. 1A) . We derived fibroblast cell lines from skin biopsies of these individuals. ALDH2 activity was significantly reduced in ALDH2*2/1 cell lysates relative to wild-type controls (Fig. 1B) . Alda-1, a specific small-molecule activator of ALDH2 (2, 33) , increased ALDH2 activity in both wild-type and ALDH2*2/1 cells. By contrast, the toxic aldehyde 4HNE, which inactivates ALDH2 (2), inhibited ALDH2 activity (Fig. 1B) .
To exclude contribution of other dehydrogenases, we measured ALDH2 activity in the presence of 4-methylpyrazole (4-MP), an alcohol dehydrogenase inhibitor (fig. S1, A and B), and daidzin, an ALDH2 inhibitor ( fig. S1, A and B) . We next quantified amounts of ROS in ALDH2*2/1 and wild-type human fibroblasts. In line with ALDH2's function as a detoxifying enzyme reducing aldehydic load in the cell and increasing mitochondrial integrity (2, 34), we found a significant elevation in basal amounts of ROSinALDH2*2/1 fibroblasts compared to wild-type controls (Fig. 1C) . ROS levels were also higher in ALDH2*2/1 fibroblasts compared to wild-type controls after external challenge with 4HNE ( fig. S2A) . As additional control, we confirmed that an unrelated strong ROS scavenger, the enzyme catalase, also significantly reduced cellular ROS in ALDH2*2/1 and wild-type fibroblasts (4.4 ± 0.5-fold and 2.9 ± 0.2-fold, respectively; fig. S2B ). Moreover, neither Alda-1 nor 4HNE interfered with the cellular ROS readout in an independent enzymatic reaction ( fig. S3, A and B) , and ALDH2 protein expression levels were comparable in ALDH2*2/1 versus wild type (Fig. 1, D and E) .
Having established specificity and efficacy in our experimental platform, Fig. 1 . Analysis of a human model system for the ALDH2*2/1 polymorphism reveals that reduced ALDH2 enzymatic activity correlates with increased levels of ROS and 4HNE in ALDH2*2/1 cells. (A) Genotyping of skin biopsy-derived fibroblasts confirms the ALDH2 wild type (wt) or heterozygous 2*2/1 mutation. In ALDH2*2/1, the G peak corresponding to the single remaining wt allele is strongly reduced and overlaid by the A peak of the mutated allele. (B) Enzymatic activity of ALDH2 in lysates from ALDH2*2/1 human fibroblasts (n = 5) is strongly reduced compared to that in wt control (n = 4). ALDH2-specific small molecules were used as a control for specificity. The ALDH2 activator Alda-1 enhances enzymatic activity, whereas the ALDH2 inhibitor 4HNE has the opposite effect. we subsequently measured amounts of endogenous 4HNE in ALDH2*2/1 and wild-type fibroblast by quantification of 4HNE-adducted proteins, as previously reported (2) . 4HNE amounts were found to be significantly increased (3.5 ± 0.8-fold; P = 0.01, as determined by Student's t test) in ALDH2*2/1 cell lysates compared to wild-type controls (Fig. 1, F 
and G).
4HNE-and ROS-induced cell cycle arrest in ALDH2*2/1 cells Elevated cellular levels of 4HNE trigger a variety of deleterious effects such as a disturbance in the cell's metabolic balance (11, 16, 32, 34 ) and inhibition of cell proliferation (35, 36) . We also observed slower growth rates in isolated cultures of ALDH2*2/1 fibroblasts compared to wildtype control fibroblasts by measuring cellular growth and viability 48 hours after plating equal numbers of cells per group. Cell numbers and viability levels for ALDH2*2/1 fibroblasts were significantly reduced compared to wild-type controls (42.5 ± 16.9%; P < 0.01; Fig. 2A ; and 54.6 ± 18.6%; P < 0.01, as determined by Student's t test; Fig. 2B ). Activation of ALDH2 in ALDH2*2/1 fibroblasts with Alda-1 restored cell growth and viability to wild-type control levels, indicating that the cellular deficiencies were directly dependent on the ALDH2*2/1 genotype. By contrast, a challenge with 80 mM 4HNE had no apparent effect on wild-type controls but did decrease proliferation of ALDH2*2/1 fibroblasts by 1.7-fold (P < 0.05, as determined by Student's t test; Fig. 2A ) and cellular viability by 2.2-fold (P < 0.001, as determined by Student's t test; Fig. 2B ), indicating a greater sensitivity of ALDH2*2/1 cells to toxic aldehydic load.
To determine whether diminished cell growth rates of ALDH2*2/1 cells were caused by a cell cycle defect, we next cultured wild-type control and ALDH2*2/1 fibroblasts for 24 hours in the presence of bromodeoxyuridine (BrdU) to label DNA in actively dividing nuclei. Strikingly, we found that the ratio of BrdU (dividing nuclei) to 4′,6-diamidino-2-phenylindole (DAPI) (total number of nuclei) was significantly reduced in ALDH2*2/1 fibroblasts relative to wild type (Fig. 2, C and D) .
Together, these data establish that the ALDH2*2 genotype is associated with increased cellular levels of 4HNE and concomitantly increased ROS, which directly correlate with reduced cell viability and proliferation. We suggest that 4HNE-and ROS-induced cell cycle arrest in ALDH2*2/1 cells is a possible underlying mechanism.
Recapitulation of increased susceptibility to ischemia in ALDH2*2 iPSC-CMs To further elucidate the underlying principles in a human cardiomyocyte model system, we moved to human iPSC-CMs. We reprogrammed ALDH2*2/1 and wild-type fibroblasts to bona fide iPSCs (figs. S4 and S5, and table S1) and then differentiated them into beating iPSC-CMs as described previously (figs. S6 and S7, tables S2 and S3, and videos S1 and S2) (37, 38) . We also confirmed equal expression of ALDH2 in ALDH2*2/1 and wild-type iPSC-CMs ( fig. S8 ). Our previous findings established increased ROS levels as well as a higher sensitivity in response to 4HNE challenge in ALDH2*2/1 fibroblasts (Fig. 2, A and B, and fig. S2A ). Therefore, we hypothesized that reduced viability caused by the loss-of-function mutation in the gene encoding mitochondrial ALDH2 might be linked to increased ROS production, due to elevated aldehydic load and mitochondrial dysfunction. Analysis of ROS levels in wild-type and ALDH2*2/1 iPSC-CMs indeed revealed a boost of ROS in the latter cells, especially after in vitro ischemic challenge using an ischemia-mimetic solution (39) combined with hypoxia ( Fig. 3,  A and B ). An elevation in ROS was dependent on reduced ALDH2 function in ALDH2*2/1 iPSC-CMs, because Alda-1-mediated activation of ALDH2 significantly reduced excess ROS in post-ischemic ALDH2*2/1 iPSC-CMs (23.0 ± 2.1%; P = 0.015, as determined by Student's t test; Fig. 3B ). As further confirmation of our assay system, we also demonstrated that elevated ROS in ALDH2*2/1 iPSC-CMs, especially after ischemia, could be reduced by the addition of catalase, an independent ROS scavenger, to the cultures ( fig. S9 ).
To determine whether elevated amounts of ROS in ALDH2*2/1 iPSCCMs impaired the cellular mitochondria-dependent metabolic balance as a consequence, we next assessed the mitochondrial membrane potential (MMP). The eletrochemical gradient and potential difference across the mitochondrial membrane represents a key indicator for cellular metabolism and health. We quantified the 590:525-nm fluorescence ratio of the cationic-potential sensor dye JC1 in ALDH2*2/1 and wild-type iPSC-CMs and found that simulated ischemia in vitro as described above did not affect the MMP of wild-type control iPSCCMs but significantly reduced the MMP of ALDH2*2/1 iPSC-CMs (59.4 ± 15.3%; P < 0.05, as determined by Student's t test; fig. S10 ). Together, our data recapitulate the phenotype of the ALDH2*2 mutation in iPSC-CMs under ischemic conditions. No differences were noted under control conditions when comparing ALDH2*2/1 to wildtype iPSC-CMs, except for a reduced metabolic rate in ALDH2*2/1 iPSC-CMs, reflected by diminished oxygen consumption ( fig. S11 ). However, ALDH2*2/1 iPSC-CMs were found to be overall significantly more affected by ischemic challenge in vitro than wild-type controls.
Apoptosis-induced increase of ischemic damage in ALDH2*2/1 cardiomyocytes Overall, these cellular profiling experiments have characterized the deleterious phenotypic and functional effects of the ALDH2*2 mutation in cardiomyocytes, especially with regard to ischemic challenge. Our data revealed that the great reduction of ALDH2 function in ALDH2*2/1 iPSC-CMs is connected to elevated ROS levels as well as a disturbed mitochondrial integrity and metabolic balance, resulting in reduced cellular viability.
On the basis of these findings, we decided to establish whether the higher sensitivity to ischemic challenge noted in ALDH2*2/1 iPSC-CMs also affects cellular viability. Using a high-content spectrophotometric approach, we found cellular viability in post-ischemic ALDH2*2/1 iPSC-CMs to be 2.3-fold lower, compared to equally ischemia-treated wild-type controls (Fig. 3, C and D) . Activation of ALDH2 has been shown to partially overcome ischemic damage in cardiomyocytes (2) . Accordingly, Alda-1-mediated ALDH2 activation before ischemic challenge improved the viability of ALDH2*2/1 iPSC-CMs after ischemia by 52.1 ± 8.0% (P < 0.05, as determined by Student's t test; Fig. 3D ).
We next performed TUNEL (terminal deoxynucleotidyl transferasemediated deoxyuridine triphosphate nick end labeling) staining to investigate whether 4HNE-and ROS-associated loss of viability and increased ischemic damage in ALDH2*2/1 iPSC-CMs were associated with apoptosis. After ischemic challenge, TUNEL-positive nuclei were 4.4 ± 0.4-fold enriched in ALDH2*2/1 iPSC-CMs but not in wild-type controls (Fig. 3, E and F) . ALDH2*2/1 iPSC-CMs also showed fragmented DNA after ischemia (Fig. 3G) . Together, these experiments establish a proapoptotic phenotype in post-ischemic ALDH2*2/1 iPSCCMs compared to wild-type control iPSC-CMs.
Identification of signaling mechanisms underlying increased ischemic damage in ALDH2*2/1 cardiomyocytes To further analyze the molecular basis of increased apoptosis after ischemia, we next performed genome-wide RNA sequencing in ALDH2*2/1 and wild-type control iPSC-CMs by comparing control and post-ischemic conditions. On the basis of changes in expression levels of 26,000 genes, Ingenuity Pathway Analysis (IPA) revealed significant up-regulation of mitogen-activated protein kinase (MAPK), apoptosis, redox, and ROS metabolism pathways in ALDH2*2/1 iPSC-CMs after ischemia, whereas cell cycle signaling was strongly reduced (Fig. 4, A and B, and tables S4 and S5). These data are in line with our previous findings of increased cell cycle arrest in ALDH2*2/1 fibroblasts (Fig. 2, C and D) and altered metabolism in ALDH2*2/1 iPSC-CMs (figs. S10 and S11). IPA-based mapping of significantly altered genes involved in these pathways (Fig. 4B ) demonstrated drastic changes in apoptotic and cell cycle signaling, as well as metabolism expression profiles in ALDH2*2/1 iPSC-CMs, especially after ischemia.
JUN expression was highly up-regulated in ALDH2*2/1 iPSC-CMs, again especially after ischemia (Fig. 4C) . Previously, increased expression of JUN has been described to inhibit proliferation and induce apoptosis (40, 41) . The JUN-encoded c-Jun protein exerts control of gene transcription via the activating protein 1 complex and can induce apoptotic and necrotic cell death (41, 42). c-Jun is regulated by the Jun N-terminal kinase (JNK), which is activated by increased levels of ROS (43, 44) . Therefore, we reasoned that ROS-mediated, prolonged activation of JNK in post-ischemic ALDH2*2/1 iPSC-CMs might lead to c-Jun-mediated downstream apoptotic signaling. Consistent with this notion, mRNA transcripts that encode the positive JNK regulator GADD45B (45) were up-regulated in post-ischemic ALDH2*2/1 iPSC-CMs. On the other hand, DUSP7, DUSP11, and DUSP18 transcripts, which encode the JNK-inactivating , and expression was normalized to human 18S expression. Data are expressed as means ± SEM. **P < 0.01 and ***P < 0.001, as calculated by Student's t test. Experiments were performed in three independent cell lines per group, quantifying 10 images each. All data are expressed as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, as calculated by Student's t test.
phosphatases DUSP7, DUSP11, and DUSP18, respectively (46), were significantly down-regulated (Fig. 4D ) compared to control. Relative mRNA expression patterns were confirmed by qRT-PCR analysis (Fig. 4, E to G,  and fig. S12 ).
Restoration of regular ROS levels and cell cycle progression by JNK inhibition
We next hypothesized that in ALDH2*2/1 iPSC-CMs, elevated levels of ROS and 4HNE might result in enhanced JNK activation and a subsequent increase in c-Jun-mediated apoptotic signaling and cell death. Therefore, to test whether inhibition of JNK signaling can reverse increased ischemic damage in ALDH2*2/1 iPSC-CMs, we used a JNK-specific inhibitor, JNK-interacting protein 1(JIP) (47) . JNK inhibition significantly reduced endogenous ROS levels in postischemic ALDH2*2/1 iPSC-CMs (27.6 ± 1.4%; P = 0.01, as determined by Student's t test; Fig. 5A ). To evaluate the effects of ROS-enhanced JNK up-regulation in post-ischemic ALDH2*2/1 iPSC-CMs, we also challenged wild-type and ALDH2*2/1 iPSC-CMs with H 2 O 2 before ischemia (Fig. 5B) . Although wild-type iPSC-CMs were not significantly affected, ALDH2*2/1 iPSC-CMs were highly sensitive to external ROS challenge with H 2 O 2 . Moreover, JNK inhibition with JIP significantly reduced ROS susceptibility in post-ischemic ALDH2*2/1 iPSC-CMs even in the presence of H 2 O 2 (34.4 ± 4.9%; P = 0.002, as determined by Student's t test; Fig. 5B ).
To confirm enhanced activation of JNK in post-ischemic ALDH2*2/1 iPSC-CMs, we analyzed lysates from post-ischemic ALDH2*2/1 and wild-type iPSC-CMs by immunoblotting and found increased phospho-JNK levels in ALDH2*2/1 iPSC-CMs (Fig. 5, C and D, and table S6 ). In line with our hypothesis, treatment of ALDH2*2/1 iPSC-CMs with JIP before ischemic challenge resulted in reduced levels of phospho-JNK (Fig. 5, C and D, and table S6 ). Activation of ALDH2 via Alda-1 before ischemic challenge showed comparable results, verifying that ALDH2-mediated ROS regulation directly affects JNK activity, with important consequences for cell survival after ischemia.
To further corroborate these findings, we established that application of JNK inhibitors (SP600125 and JIP) to ALDH2*2/1 fibroblasts can recover viability in these cells (Fig. 5E) . Rescue of viability in ALDH2*2/1 fibroblasts can also be achieved by small interfering RNA (siRNA)-mediated knockdown of JUN (Fig. 5F ). Finally, JNK inhibition with JIP also reversed cell cycle arrest in ALDH2*2/1 fibroblasts (Fig. 5, G and H) . Together, these data imply that in post-ischemic cells with the ALDH2*2/1 genotype, proapoptotic signaling events as confirmed by transcriptome analysis (Fig. 4) are mediated via JNK and triggered through excess ROS, caused by greatly reduced ALDH2 function in ALDH2*2/1 cells.
ALDH2 as modulator in a cell survival-regulating cascade
These findings indicate a role of ALDH2 in the regulation of cell survival decisions via modulation of cellular ROS levels, which affects JNK-mediated downstream signaling and, eventually, c-Jun-dependent transcription of proapoptotic genes. To further support this hypothesis, we tested whether JNK inhibition before ischemic challenge can restore viability of ALDH2*2/1 iPSC-CMs. Using two independent JNK inhibitors (SP600125 and JIP), we found that the viability of post-ischemic ALDH2*2/1 iPSC-CMs was restored to levels found in nonischemic, untreated ALDH2*2/1 iPSC-CMs (Fig. 6, A and B) . Quantification of TUNEL-positive nuclei (Fig. 6, C and D) also revealed reduced apoptosis in JIP-treated ALDH2*2/1 iPSC-CMs subjected to ischemia, implying a rescue from ischemia-associated damage. Collectively, our data indicate that cells with the ALDH2*2 loss-of-function mutation cannot efficiently control ROS levels, a deficiency that is linked to subsequent JNK-mediated downstream signaling, which leads to defective cell cycle signaling and, especially after ischemic challenge, c-Junmediated cell death signaling (Fig. 6E ).
DISCUSSION
Here, we used a human iPSC-CM platform to investigate the molecular mechanisms underlying the cardiac disease phenotypes observed in carriers of the dominant-negative ALDH2*2 genetic polymorphism.
Analysis and characterization of human ALDH2*2/1 iPSC-CMs revealed no significant differences compared to wild-type control iPSCCMs under normoxic conditions; however, relative to wild type, ALDH2*2/1 iPSC-CMs were highly sensitive to ischemia simulated in vitro. These findings make functional sense in light of the higher incidence of MI and CAD in ALDH2*2 carriers reported previously (3, 4, 31) . Independent genome-wide association and meta-analysis studies on the determining factors associated with the genetic basis of CAD have revealed the ALDH2*2 genotype as a risk factor for CAD (5, 48, 49) . Carriers of the ALDH2*2 polymorphism in Chinese, Korean, and Japanese populations were found to display an increased susceptibility to both MI and CAD. In addition, studies in animal models have shown that the ALDH2*2 genotype is more susceptible to oxidative damage than wild-type animals and that oxidative stressmediated inhibition of ALDH2 causes cardiac dysfunction (16) . Oxidative stress and ROS have been reported to play major roles in CAD pathogenesis (50) . During MI, ROS not only directly cause cell injury but also induce signaling events that contribute to cellular dysfunction, including damage of membranes and degradation of extracellular matrix components. The resulting structural changes induce left ventricular (LV) dilatation and, consequently, LV remodeling after MI (50, 51) .
We show here that under ischemic conditions, ALDH2*2/1 iPSCCMs displayed significantly elevated levels of ROS and apoptosis. Transcriptome profiling identified differences in ROS, cell cyclerelated, and apoptosis signaling pathways and strong up-regulation of JUN and related transcripts. Thus, we reasoned that in ALDH2*2/1 iPSC-CMs, especially after ischemia, c-Jun-related apoptotic signaling might be caused by enhanced ROS-mediated activation of JNK. This is in line with previous evidence that JNK/c-Jun can negatively regulate cell proliferation (40) .
Indeed, JNK inhibition reversed ROS sensitivity of ALDH2*2/1 iPSC-CMs after ischemia and restored viability to wild-type control levels. Our findings also demonstrated that in ALDH2*2/1 cells, an increase in 4HNE load and subsequent ROS accumulation induced downstream signaling events that led to reduced viability and cell death-a process that is further enhanced during ischemic stress-and that these events functioned via JNK and its downstream effecter c-Jun, enhancing transcription of proapoptotic genes. Mitochondrial ALDH2 metabolizes and inactivates the ROS enhancer 4HNE. Hence, impaired ALDH2 function in the ALDH2*2 genotype causes elevated levels of ROS and 4HNE, which support sustained JNK activation and c-Jun-mediated induction of apoptosis. Consequently, the lack of ALDH2-dependent ROS scavenging renders ALDH2*2/1 iPSC-CMs more susceptible to ischemic damage.
Both activation of ALDH2 and inhibition of JNK can partially reverse these deleterious effects in ALDH2*2/1 cells.
We propose that the ALDH2*2 genotype is associated with defective regulation of ALDH2-dependent signaling events, which induces apoptosis and results in increased damage of ALDH2*2 iPSC-CMs during ischemia. These findings reveal a newly identified regulatory loop that provides insight into novel functions of ALDH2. We have discovered a direct link between ALDH2 activity and cell survival decisions by describing new aspects of mitochondrial ALDH2's cardioprotective function.
Pinpointing the molecular basis underlying ALDH2-mediated cardioprotection has potential implications for the treatment of ischemic activity, such as that occurring in the ALDH2*2 genotype, leads to elevated 4HNE and increased ROS, which activates JNK and leads to downstream proapoptotic signaling events. These events are enhanced during ischemic challenge, which triggers additional ROS. In ischemic ALDH2*2/1 iPSC-CMs, accumulating 4HNE and unscavenged ROS build up over time, causing higher levels of JNK activity and downstreamc-Jun-dependent activation of apoptotic genes. ALDH2 activation via Alda-1 as well as JNK inhibition via JIP can rescue the proapoptotic phenotype in post-ischemic ALDH2*2/1 iPSC-CMs, whereas 4HNE inhibits ALDH2. All data are expressed as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, calculated by Student's t test.
heart disease and regenerative medicine therapy in human carriers of the ALDH2*2 genetic polymorphism.
MATERIALS AND METHODS
Please see Supplementary Methods for full details.
Study design
To investigate the molecular mechanisms underlying increased ischemic damage in the ALDH2*2/1 genotype, a cohort of 10 consenting, 21-to 22-year-old male individuals of East Asian origin and with no family relations were recruited. Skin punch biopsies were digested using Collagenase IV and were kept in GlutaMAX-containing Dulbecco's modified Eagle's medium (Life Technologies) supplied with 10% fetal bovine serum (Gibco) under sterile culture conditions at 37°C. After 1 week, outgrowing fibroblast cell lines were subjected to genotyping. On the basis of the genotyping results, cell lines were grouped into control (wild-type ALDH2 genotype, n = 5) or heterozygous ALDH2 mutant (ALDH2*2/1, n = 5).
Genotyping
The ALDH2*2/1 genotype was determined by isolating genomic DNA from~5 × 10 6 human fibroblasts per each line using a DNeasy Blood & Tissue kit (Qiagen) according to the manufacturer's instructions. A~300-base pair (bp) stretch of DNA upstream and downstream of the point mutation E487K was amplified via PCR using the following primers: ALDH2 E487K: forward, 5′gtcaactgctatgatgtgtttggagccc3′; reverse, 5′caagcatgagggagaggccaaaagg3′. PCR products were run on a 2% agarose gel, and DNA was extracted using a QIAquick Gel Extraction Kit (Qiagen) and sequenced at Quintara Biosciences (San Francisco) using the primers ALDH2 E487K-forward and ALDH2 E487K-reverse, respectively.
Cardiac differentiation of iPSCs
Human iPSCs were grown to 90% confluence (52) (53) (54) , after which iPSCs were differentiated into beating cardiomyocytes using a small molecule-based monolayer method (37) as described in detail previously (38) . After differentiation, human iPSC-CMs were cultured in RPMI medium plus B-27 Supplement (Life Technologies). iPSCCMs expressed typical cardiac markers such as cardiac troponin T (TNNT2), sarcomeric a-actinin, and myosin light chain 2a and showed electrophysiological profiles effective of atrial-, nodal-, and ventricularlike cells as well as normal calcium transients. About 30 days after cardiac differentiation, beating iPSC-CM monolayers were dissociated using TripleE (10 min) or Accutase (30 min), washed, and plated in the respective assay format.
Measurement of ALDH2 activity
Cell lysates (200 mg) were added into a cuvette containing activity assay buffer and substrate [50 mM sodium pyrophosphate buffer at pH 9.0, 2.5 mM NAD + (nicotinamide adenine dinucleotide), 10 mM acetaldehyde, and 460 ml of H 2 O] with a final volume of 2 ml. Optical density at A 340 nm was measured at 25°C for increase of NADH (reduced form of NAD + ) for 5 min. Blank control was no acetaldehyde. To show ALDH2 sensitivity of this assay, the ALDH2-specific smallmolecule activator Alda-1 (20-mM final concentration) or the ALDH2-specific inhibitor daidzin (50 mM final concentration) was added to the lysates. When indicated, 4-MP, an alcohol dehydrogenase inhibitor, was preincubated with the lysates at 200-mM final concentration for 1 hour before measurements.
Measurement of ROS
Fibroblasts or iPSC-CMs cultured on 96-well plates were treated with small molecules or vehicle control as indicated below. Subsequently, basal cellular levels of ROS were determined using an Amplex Red assay kit (Life Technologies) according to the manufacturer's instructions. The Amplex Red assay is a measure of cellular ROS by specific detection of cellular H 2 O 2 resulting from degrading intracellular free radicals, such as superoxide. Cellular H 2 O 2 and horseradish peroxidase present in the Amplex Red assay convert Amplex Red reagent to its fluorescent product, resorufin. Fluorescence emitted by this reaction was measured at 562 nm using a GloMax spectrophotometer plate reader (Promega). Other than as indicated in the figure, no additional external ROS challenge was added to the cells. An H 2 O 2 standard curve was used for confirming the assay's sensitivity and background signal. Specificity of this reaction was further confirmed by pretreating fibroblasts or iPSC-CMs, where indicated, for 4 hours with an unrelated ROS scavenger, catalase. To exclude interference of Alda-1 and 4HNE with the Amplex Red experimental readout, a Xanthine/Xanthine Oxidase Amplex Red-based assay kit (Life Technologies) was used according to the manufacturer's instructions. Alternatively, cellular ROS were detected by addition of the fluorogenic dye 5-(and-6)-carboxy-2′,7′-dichlorofluorescein diacetate (DCFDA, Life Technologies) according to the manufacturer's instructions.
RNA sequencing and data analysis RNA was isolated from ALDH2*2/1 and wild-type control iPSC-CMs (n = 2 per group) using a Qiagen microRNA kit, and 100 ng of total RNA was converted to complementary DNA (cDNA) and amplified using NuGEN V2 RNA-Seq kit (NuGEN). cDNA was sonicated to an average fragment size of 300 bp, and Illumina sequencing adapters were ligated to 500 ng of cDNA using NEBNext mRNA Library Prep Reagent Set for Illumina (New England Biolabs). PCR was performed on the adapter-ligated cDNA under the following conditions: denaturation at 98°C for 30 s, followed by eight cycles of denaturation at 98°C for 10 s, annealing at 65°C for 30 s, and extension at 72°C for 30 s, ending with an additional extension at 72°C for 5 min. Sequencing was performed using Illumina's HiSeq2000 platform using paired in reads at an average length of 100 bp (2 × 100). Reads were filtered to produce an average of 60 million reads per sample and were aligned via the hg19 reference genome using TopHat version 2.0.8b (PMID 19289445) . Differentially regulated transcripts and gene expression levels were ascertained using Cufflinks v2.1.1 (55) algorithms. 
Statistical analysis
An unpaired Student's t test was used to calculate significances between two groups. If the data were normally distributed, a one-way analysis of variance (ANOVA) was used, and multiple comparison correction analysis was performed. A P value of <0.05 was considered statistically significant.
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